What’s Next For Alnylam Pharmaceuticals After A 50% Rally?
- Friday, July 3, 2020, 7:16
- Market
- Add a comment
The stock price of Alnylam Pharmaceuticals, a pharmaceutical company best known for its ribonucleic acid interference therapeutics for genetically defined diseases, has rallied around 50% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $149 after falling to a low of..
About the Author
admin123 has written 23400 stories on this site.
